Difference between revisions of "Paroxetine-fluoxetine"

From Psychiatrienet
Jump to: navigation, search
 
(5 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
| to = fluoxetine  
 
| to = fluoxetine  
 
| stop =  
 
| stop =  
* Gradually reduce dosage of paroxetine to a maximum of 20 mg/ day, when this dosage is > 20 mg/day.
+
{{stopParoxetine}}
* When a dosage of 20 mg/day is reached, stop administration.
 
 
| start =  
 
| start =  
* No wash-out period is needed.  
+
* '''Day 1:''' start fluoxetine at 100% of the target dose.
* Start fluoxetine the next day in normal dosage of 20 mg/day.
+
* ''' After 2 weeks:''' If necessary, gradually increase dosage of fluoxetine.
 
| info =
 
| info =
* {{theorSS}}
+
* Safe target dose fluoxetine = 20 mg
{{review}}
+
* Fluoxetine and paroxetine are both strong inhibitors of CYP2D6.
 
}}
 
}}

Latest revision as of 14:09, 8 March 2024

paroxetine
Type Antidepressant
Group SSRI
links
Medscape paroxetine
PubChem 43815
PubMed paroxetine
Kompas (Dutch) paroxetine
Wikipedia paroxetine
Fluoxetine
Type Antidepressant
Group SSRI
links
Medscape Fluoxetine
PubChem 3386
PubMed Fluoxetine
Kompas (Dutch) Fluoxetine
Wikipedia Fluoxetine

Switch medication from paroxetine to fluoxetine.[1] [2]

Nietinrijdenbord.png Stop paroxetine
  • Before day 1: gradually reduce dosage of paroxetine to a maximum of 20 mg/day when this dosage is > 20 mg/day.
  • Day 1: reduce dosage of paroxetine to a maximum of 10 mg/day.
  • Day 8: stop administration of paroxetine.
Eenrichtingbord.png Start fluoxetine
  • Day 1: start fluoxetine at 100% of the target dose.
  • After 2 weeks: If necessary, gradually increase dosage of fluoxetine.
Infobord.png More information
  • Safe target dose fluoxetine = 20 mg
  • Fluoxetine and paroxetine are both strong inhibitors of CYP2D6.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.